5-Aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression

Cancer Letters

Volumn 311, Issue 2, 2011, Pages 230-236

  Shang, Donghao ^a   Liu, Yuting ^b   Xu, Xiuhong ^a   Han, Tiandong ^a   Tian, Ye ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

catenin; DAC; LEF1; PTX; Renal cell carcinoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA CATENIN; COMPLEMENTARY DNA; LYMPHOID ENHANCER FACTOR 1; PACLITAXEL; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENTIATION; EXPRESSION VECTOR; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; DRUG SYNERGISM; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LYMPHOID ENHANCER-BINDING FACTOR 1; MICE; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053130814     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.012     Document Type: Article

References (37)

1. Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. 2003, 30(4):843-852.
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M.J. Cancer statistics 2006. CA Cancer J. Clin. 2006, 56(2):106-130.
3. Yu D.S., Chang S.Y., Ma C.P. The expression of MDR-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br. J. Urol. 1998, 82(4):544-547.
4. Hartmann J.T., Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res. 1999, 19(2C):1541-1543.
5. Ravaud A., Audhuy B., Gomez F., Escudier B., Lesimple T., Chevreau C., Douillard J.Y., Caty A., Geoffrois L., Ferrero J.M., Linassier C., Drevon M., Négrier S. Subcutaneous interleukin-2, interferon-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. J. Clin. Oncol. 1998, 16(8):2728-2732.
6. Atzpodien J., Kirchner H., Hänninen E.J., Deckert M., Fenner M., Poliwoda H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur. J. Cancer 1993, 29A(Suppl. 5):56-58.
7. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27(22):3584-3590.
8. Chouhan J.D., Zamarripa D.E., Lai P.H., Oramasionwu C.U., Grabinski J.L. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. J. Oncol. Pharm. Pract. 2007, 13(1):5-15.
9. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R.M. TARGET Study Group: sorafenib in advanced clear-cell renal-cell carcinoma. New Engl. J. Med. 2007, 356(2):125-134.
10. Ryan C.W., Goldman B.H., Lara P.N., Mack P.C., Beer T.M., Tangen C.M., Lemmon D., Pan C.X., Drabkin H.A., Crawford E.D. Southwest oncology group. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J. Clin. Oncol. 2007, 25(22):3296-3301.
11. Gollob J.A., Rathmell W.K., Richmond T.M., Marino C.B., Miller E.K., Grigson G., Watkins C., Gu L., Peterson B.L., Wright J.J. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 2007, 25(22):3288-3295.
12. Willemze R., Suciu S., Archimbaud E., Muus P., Stryckmans P., Louwagie E.A., Berneman Z., Tjean M., Wijermans P., Dohner H., Jehn U., Labar B., Jaksic B., Dardenne M., Zittoun R. A randomized phase II study on the effects of 5-aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997, 11(Suppl. 1):S24-27.
13. Lübbert M., Daskalakis M., Kunzmann R., Engelhardt M., Guo Y., Wijermans P. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine). Leuk Res. 2004, 28(12):1267-1271.
14. Shang D., Liu Y., Matsui Y., Ito N., Kamoto T., Ogawa O. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology 2008, 71(6):1220-1225.
15. Shang D., Liu Y., Liu Q., Zhang F., Feng L., Lv W., Tian Y. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett. 2009, 278(1):82-87.
16. Shang D., Ito N., Kamoto T., Ogawa O. Demethylating agent 5-aza-2-deoxycytidineenhances susceptibility of renal cell carcinoma to paclitaxel. Urology 2007, 69(5):1007-1012.
17. Travis A., Amsterdam A., Belanger C., Grosschedl R. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function. Genes Dev. 1991, 5(5):880-894.
18. Waterman M.L., Fischer W.H., Jones K.A. A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev. 1991, 5(4):656-669.
19. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997, 11(24):3286-3305.
20. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103(2):311-320.
21. Nusse R. WNT targets: repression and activation. Trends Gen. 1999, 15(2):1-3.
22. Eichhoff O.M., Weeraratna A., Zipser M.C., Denat L., Widmer D.S., Xu M., Kriegl L., Kirchner T., Larue L., Dummer R., Hoek K.S. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigm. Cell Melanoma Res. 2011, 20. Epub ahead of print.
23. Li T.W., Ting J.T., Yokoyama N., Bernstein A., van de Wetering M., Waterman M. Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol. Cell. Biol. 2006, 26(14):5284-5299.
24. Dutta K.K., Nishinaka Y., Masutani H., Akatsuka S., Aung T.T., Shirase T., Lee W.H., Yamada Y., Hiai H., Yodoi J., Toyokuni S. Two distinct mechanisms for loss of thioredoxin-biding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest. 2005, 85(6):798-807.
25. Liu Y., Shang D., Akatsuka S., Ohara H., Dutta K.K., Mizushima K., Naito Y., Yoshikawa T., Izumiya M., Abe K., Nakagama H., Noguchi N., Toyokuni S. Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate β-catenin pathway. Am. J. Pathol. 2007, 171(6):1978-1988.
26. Li Y., Wang L., Zhang M., Melamed J., Liu X., Reiter R., Wei J., Peng Y., Zou X., Pellicer A., Michael J., Ferrari A., Lee P. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 2009, 69(8):3332-3338.
27. Yun K., Im S.H. Lef1 regulates COX-2 transcription in chondrocytes. Biochem. Biophys. Res. Commun. 2007, 364(2):270-275.
28. Pellagatti A., Marafioti T., Paterson J.C., Malcovati L., Della Porta M.G., Jädersten M., Pushkaran B., George T.I., Arber D.A., Killick S., Giagounidis A., Hellström-Lindberg E., Cazzola M., Wainscoat J.S., Boultwood J. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br. J. Haematol. 2009, 146(1):86-90.
29. Feigin M.E., Malbon C.C. OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling. Cell Signal 2008, 20(5):949-957.
30. Watermann M.L. Lymphoid enhance factor/T cell factor expression in colorectal cancer. Cancer Metast. Rev. 2004, 23(1-2):41-52.
31. Pawlowski J.E., Ertel J.R., Allen M.P., Xu M., Butler C., Wilson E.M., Wierman M.E. Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J. Biol. Chem. 2002, 277(23):20702-20710.
32. Truica C.I., Byers S., Gelmann E.P. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000, 60(17):4709-4713.
33. Brantjes H., Barker N., van Es J., Clevers H. TCF: Lady Justice casting the final verdict on the outcome of Wnt signaling. Biol. Chem. 2002, 383(2):255-261.
34. Nguyen D.X., Chiang A.C., Zhang X.H., Kim J.Y., Kris M.G., Ladanyi M., Gerald W.L., Massagué J. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009, 138(1):51-62.
35. Lin A.Y., Chua M.S., Choi Y.L., Yeh W., Kim Y.H., Azzi R., Adams G.A., Sainani K., van de Rijn M., So S.K., Pollack J.R. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One 2011, 6(2):e16636.
36. Gutierrez A., Sanda T., Ma W., Zhang J., Grebliunaite R., Dahlberg S., Neuberg D., Protopopov A., Winter S.S., Larson R.S., Borowitz M.J., Silverman L.B., Chin L., Hunger S.P., Jamieson C., Sallan S.E., Look A.T. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010, 115(14):2845-2851.
37. Gehrke I., Gandhirajan R.K., Kreuzer K.K. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: multiplicity of therapeutic options. Eur. J. Cancer 2009, 45(16):2759-2767.